B7/BB1 is a membrane differentiation antigen expressed on activated B cells, macrophages, and dendritic cells that binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes. Interaction between CD28 and B7 results in potent costimulation of T cell activation initiated via the CD3/T cell receptor complex. We now report that B7 is also expressed on activated human peripheral blood T cells, CD4 T cell clones, CD8 T cell clones, and natural killer cell clones. B7 appears relatively late after T cell activation, can be detected on both CD4 and CD8 T cell subsets, and is present on antigen-specific, major histocompatibility complex-restricted CD4 and CD8 T cell clones. Expression of B7 on activated T cells was confirmed by immunoprecipitation from 12SI-labded activated T cells and by detection of B7 transcripts. A B7 ~ CD4 + T cell clone was able to stimulate a primary allogeneic mixed lymphocyte response using small, resting peripheral blood T cells as responders. The alloantigen-induced proliferative response and cytokine production was partially inhibited by anti-B7 monoclonal antibody. Since activated T cells can coexpress both CD28 and its counter-receptor, B7, this suggests that activated T cells may be capable of autocrine costimulation via the CD28 activation pathway.
B
7/BB1 is a cell surface antigen expressed on activated B cells, macrophages, and dendritic cells (1) (2) (3) . While B7 is constitutively expressed on dendritic cells (3) , it is only present in substantial levels after activation of B cells and monocytes. This antigen is upregulated on B cells after infection with EBV (2) or after stimulation with anti-Ig (1) or anti-HLA-DR (4) . Levels of B7 expression induced by anti-Ig can be increased by Ib2 or II-4 (5). IFN-3, is capable of inducing B7 expression on monocytes (6) . B7 is a 50-70-kD glycoprotein and is encoded by a gene that is a member of the Ig superfamily (7) . B7 binds to CD28 (8) , a cell surface disulfide-linked homodimer that is constitutively expressed on thymocytes and the majority of T lymphocytes (9, 10) . The interaction between CD28 and B7 results in augmentation of T cell activation initiated through the TCR (4, 8, (11) (12) (13) . CD28 costimulation of T cells results in induction of II.-2 transcription (14) and stabilization of cytokine mRNA (15) , and is resistant to inhibition by r A (16) . In a prior study, it was observed that HTLV-I-transformed T cells may also express B7 (17) , suggesting the possibility that T cells may coexpress both CD28 and its counter-receptor under certain i The first two authors contributed equally to these studies.
circumstances. Herein, we have investigated whether normal, nontransformed T cells are capable of expressing functional B7 antigens.
Materials and Methods
Preparation of Lymphocytes and Cell Culture. Human peripheral blood was obtained from the Stanford Blood Center (Palo Alto, CA). PBMC were isolated by Ficoll/Hypaque gradient centrifugation. Small, resting T cells were isolated using Percoll density gradients after removal of B cells and monocytes by plastic and nylon wool adherence, as previously described (13) . Cells were cultured in Yssel's modified Iscove's medium (18) or RPMI 1640 (JRH Biosdences, Lexena, KS) containing 10% FCS (JKI-I Biosdences), t-glutamine, and antibiotics. Human rlL-2 was generously provided by Dr. Gerard Zurawski (DNAX). A series of CD4 § T cell dones, CD8 + T cell clones, and NK cell clones was established from normal PBL. Clones were cultured in medium supplemented with rlI.-2 and were restimulated using PHA, irradiated PBMC, and irradiated EBV B lymphoblastoid ceils, as described previously (18) . The properties of the antigen-spedfic T cell dones have been described previously (19) (20) (21) (22) Biochemistry. Radioiodination, immunoprecipitation, and electrophoresis were performed as previously described (25,.26) . Radioactive proteins were detected using a Phosphorlmager (Molecular Dynamics, Inc., Sunnyvale, CA).
Results and Discussion
Expression of B7 on Activated T Lymphocytes and T Cell Clones. Analysis of a series of human T cell clones indicated that the majority expressed B7 on the cell surface, as determined by immunofluorescence and flow cytometry. Expression of B7 on T cell clones was not restricted to a particular subset since both CD3+CD4 + T cell clones (14 of 16 examined) and CD3+CD8 + T cell clones (14 of 14 examined) were found. Moreover, B7 was also present on CD3-CD56 + NK cell clones (five of five examined), but was not detected on freshly isolated PBL NK cells (not shown). The levels of B7 varied between different clones and ranged from very high levels of expression to undetectable. Most of the B7 + T cell clones examined coexpressed the counter-receptor, CD28, whereas all B7 + NK cell clones were CD28 negative. Representative T and NK cell clones are shown in Fig. 1 . Although the antigenic specificity of most of the T cell clones surveyed in our panel was not determined, B7 was detected on several well-characterized T cell clones of known specificity and function. For example, HY-827 is a CD4 +, HLA-DR3-restricted T cell clone that recognizes a peptide of tetanus toxoid (19) , HY-06 is a CD4 +, HLA-DR3-restricted T cell clone that recognizes mycobacterial HSP-65 antigen (20) , AG150 is a CD4 +, HLA-DR4-restricted T cell clone recognizing the DerpI house dust mite allergen (21) , and CTL Q66.40 is a CD8 + , HLA-A2-restricted T cell clone reacting with an influenza peptide (22) (Fig. 1) . The presence of B7 on T cell clones was relatively stable over time, although differences in levels of expression were observed.
The presence of B7 on most T cell clones prompted us to examine induction of this antigen on PBL T cells. Consistent with prior findings, B7 was not detected on freshly isolated PBL T cells (Fig. 2) . PBMC were stimulated with immobilized anti-CD3, and 100 IU/ml rib2 was added to the culture after 5 d. Cells were examined on days 1, 3, 5, 10, and 12 for induction of B7. Using these conditions, B7 appeared gradually on the T cells over the course of culture, and maximal expression occurred after 10 d when >80% of T cells coexpressed B7 (Fig. 2) . The majority of both CD4 and CD8 T cells were B7 + . Consistent results were obtained using PBMC from three independent donors. The relatively late induction and the low levels of expression on some T cell clones likely accounts for prior reports that activated T cells failed to express B7 (2, 17) . Biochemical Analysis ofT Cell-associated B7 Antigen. The presence orB7 on activated T cell populations and T cell clones was confirmed by immunofluorescent staining using three different mAbs against B7 (i.e., BB1, L307, L308) (not shown). Specificity of the immunofluorescent staining was substantiated by biochemical verification (Fig. 3) . A CD4 + T clone (AW27-19) and a polyclonal population of anti-CD3 and rib 2-activated PBL T cells were 12si labeled, detergent lysed, and B7 antigen was immunoprecipitated and analyzed by SDS- 
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for the ef~cient generation of a primary MLR directed against aUoantigen (13, 27) . mAbs against B7 partially inhibit an alloantigen-induced MLR (3, 4) , and transfection of B7-negative B lymphoma cell lines with B7 cDNA substantially augments their ability to stimulate a primary T cell immune response (13, 27) . The detection of B7 on activated T cells suggested that this may enable these T cells to act themselves as costimulators of a primary T cell response. Since human activated T cells express both MHC class II and class I intigens and B7, they might be expected to serve as stimulators of an allogeneic MLR. To examine this possibility, a CD4 + T cell clone expressing B7 (Fig. 1, CD4-AW27-19 ) was irradiated and used as the stimulator in a primary MLK culture using freshly isolated small, resting PBL T cells as responders. As shown in Table 1 , a vigorous MLR response was observed using small, resting PBL responder T cells from three different donors. Both the alloantigen-induced proliferative response, as well as the secretion of IFN-% were partially ('~30-50%) inhibited by the presence of anti-B7 mAb, similar to the level of inhibition observed with anti-CD4 or anti-HLA-DR mAbs (Table 1) . These results are comparable to prior reports that anti-B7 is capable of partially inhibiting alloantigen MLR generated with EBV B lymphoblastoid cells as stimulators (3, 4) . Conclusions. B7 is not restricted in expression to "conventional" APC since this glycoprotein is also present on most activated T and NK cells. The ability of B7 + activated T cell clones to stimulate a primary allogeneic MLR response substantiates the fact that expression of B7 is functionally competent. Prior studies have demonstrated that activated T and NK cell clones possess the ability to present peptide Freshly isolated small, resting PBL T cells (2 x 10 s calls/well) from three different blood donors (Exps. 1-3) were cocultured with irradiated (4,000 rad) B7 + T cell done AW27-19 (2 • 10 calls/well) in 96-well flat-bottomed plates (Falcon Labware) in a total volume of 200/~1, as indicated. Anti-BT, anti-HLA-DR, and anti-CD4 mAbs were added at 5/zg/ml. Cultures were incubated at 37~ with 5% CO2 in a humidified atmosphere for 6 d. Cultures were hbeled for the final 4 h with 1 #Ci/well [3H]thymidine (New Enghnd Nuclear, Boston, MA), were harvested using a 96-well plate harvester (LKB, Pharmacia, Piscataway, NJ), and radioactivity was measured using a ~ scintilhtion counter. Small, resting PBL T cells isolated by PercoU gradient centrifugation are unable to respond to anti-CD3 stimuhition in the absence of appropriate accessory cells (13) . The irradiated AW27-19 B7 + CD4 + T cells used as stimulators were >99% CD3 § and did not contain any detectable contaminating B cells or monocytes in the population, as determined using flow cytometric analysis. For determination of IFN-q~ secretion, supernatants from MLR cultures were harvested after 48 h, and IFN-3, was measured by an ELISA using anti-IFNw-spedfic mAb (30) . Data are expressed as IFN-3' (pg/ml) secreted per 106 cells (lower limit of detection was 50 pg/ml). * Numbers in parentheses represent percent inhibition, relative to control values.
antigens in an antigen-specific, MHC-restricted fashion, although the antigen-processing capacity of T and NK cells are limited relative to macrophages (28, 29). Since activated T cells can coexpress both CD28 and its counter-receptor, B7, this suggests the possibility that activated T calls may be capable of autocrine costimulation via the CD28 activation pathway under certain circumstances.
